WallStreetZenWallStreetZen

NASDAQ: SYRE
Spyre Therapeutics Inc Earnings & Revenue

SYRE past revenue growth

How has SYRE's revenue growth performed historically?
Company
-61.96%
Industry
188.87%
Market
18.51%
SYRE's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
SYRE's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Market Performance
SYRE's revenue growth is slowing... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

SYRE earnings and revenue history

Current Revenue
$886.0k
Current Earnings
-$338.8M
Current Profit Margin
-38,238.1%

SYRE Return on Equity

Current Company
N/A
Current Industry
-64.7%
Current Market
188%

Be the first to know when SYRE announces earnings.

SYRE Return on Assets

Current Company
-160.4%
Current Industry
6.6%
SYRE is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

SYRE Return on Capital Employed

Current Company
-109.34%
Current Industry
23.6%
SYRE's ability to generate Return... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

SYRE vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
SYRE$886.00k-$337.85M-$338.79M-25.61%N/A
TARS$17.45M-$131.13M-$135.89M-44.69%N/A
MNKD$198.96M$20.62M-$11.94M+48.17%N/A
MGNX$121.13M$64.93M$49.82M-9.24%N/A
ETNB$0.00-$133.26M-$142.19MN/AN/A

Spyre Therapeutics Earnings & Revenue FAQ

What were SYRE's earnings last quarter?

On Invalid Date, Spyre Therapeutics (NASDAQ: SYRE) reported Q4 2023 earnings per share (EPS) of $20.45, up 536.03% year over year. Total Spyre Therapeutics earnings for the quarter were -$63.18 million. In the same quarter last year, Spyre Therapeutics's earnings per share (EPS) was -$4.69.

If you're new to stock investing, here's how to buy Spyre Therapeutics stock.

What was SYRE's earnings growth in the past year?

As of Q1 2024, Spyre Therapeutics's earnings has grown year over year. Spyre Therapeutics's earnings in the past year totalled -$338.79 million.

What was SYRE's revenue last quarter?

On Invalid Date, Spyre Therapeutics (NASDAQ: SYRE) reported Q4 2023 revenue of $0.00 up 100% year over year. In the same quarter last year, Spyre Therapeutics's revenue was $168.00 thousand.

What was SYRE's revenue growth in the past year?

As of Q1 2024, Spyre Therapeutics's revenue has grown -61.96% year over year. This is 250.83 percentage points lower than the US Biotechnology industry revenue growth rate of 188.87%. Spyre Therapeutics's revenue in the past year totalled $886.00 thousand.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.